Treating to target in rheumatoid arthritis: Biologic therapies

British Journal of Nursing

Volumn 20, Issue 20, 2011, Pages 1284-1291

  Firth, Jill ^a   Critchley, Sarah ^a  

^a Pennine Musculoskeletal Partnership Ltd   (United Kingdom)

Author keywords

Biologic drugs; Rheumatoid arthritis; Treating to target

Indexed keywords

EID: 81255207846     PISSN: 09660461     EISSN: None     Source Type: Journal    
DOI: 10.12968/bjon.2011.20.20.1284     Document Type: Article

References (22)

1. Chilton F, Collett RA (2008) Treatment choices, preferences and decisionmaking by patients with rheumatoid arthritis. Musculoskeletal Care 6(1): 1-14.
2. Ding T, Ledingham J, Luqmani R et al(2010) BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology 49(11): 2217-9
3. Dixon W, Watson K, Lunt M et al (2010) Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res 62(6): 755-63
4. Emery P, McInnes IB, van Vollenhoven R Kraan MC (2008) Clinical identification and treatment of a rapidly progressing disease state in patients with rheumatoid arthritis. Rheumatology 47(4): 392-8
5. Firth J (2011) Rheumatoid Arthritis: treating to target with disease-modifying drugs. Br J Nurs 20(19): 1240-5
6. Hui M, Ding T, Deighton C (2010) An update on DMARDs and biologics. Arthritis Research UK, Derbyshire
7. Isenberg DA, Morrow J (1995) Friendly Fire: explaining autoimmune disease. Oxford University Press, Oxford
8. King's Fund (2009) Perceptions of patients and professionals on rheumatoid arthritis care. King's Fund, London
9. Lakey RL, Cawston TE (2009) Sulphasalazine blocks the release of proteoglycan and collagen from cytokine stimulated cartilage and down-regulates metalloproteinases. Rheumatology 48(10): 1208-12
10. Larsson I, Bergman S, Fridlund B, Arvidsson B (2010) Patients' independence of a nurse for the administration of subcutaneous anti-TNF therapy: A phenomenographic study. Int J Qual Stud Health Well-being Jun 30; 5
11. Lunt M, Watson K, Dixon W, Symmons D, Hyrich K, Bsr Control Centre Consortium, BBR (2010) No evidence of association between anti-TNF treatment and mortality in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 62(11): 3145-53
12. National Audit Office (2009) Services for people with rheumatoid arthritis. London, The Stationary Office.
13. National Institute For Health And Clinical Excellence (2007) Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis. NICE, London. http://www.nice.org.uk/TA130 (Accessed 27 October 2011)
14. National Institute For Health And Clinical Excellence (2009) Rheumatoid arthritis: the management of rheumatoid arthritis in adults. NICE, London. http://www.nice.org.uk/CG79 (Accessed 27 October 2011)
15. National Institute For Health And Clinical Excellence (2010) Rheumatoid arthritis-drugs for treatment after failure of a TNF inhibitor. NICE, London. http://guidance.nice.org.uk/TA/WaveR/61 (Accessed 27 October 2011)
16. National Rheumatoid Arthritis Society (2010) Biologics the story so far: A patient guide to biologic therapies in the treatment of rheumatoid arthritis. NRAS, Berkshire. http://tinyurl.com/3gbcw9c (Accessed 3 November 2011)
17. Oliver S, Leary A (2010) The value of the nurse specialist' role: Pandora initial findings. Musculoskeletal Care 8(3): 175-7
18. Palmer, D, Miedany Y (2010) Biological nurse specialist: goodwill to good practice. Br J Nurs 19(8): 477-80
19. Prevoo ML, Van T, Hof MA et al (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38(1): 44-8
20. Royal College Of Nursing (2009) Assessing, managing and monitoring biologic therapies for inflammatory arthritis: guidance for rheumatology practitioners. NICE, London
21. Smolen JS, Aletaha D, Bijlsma JW et al (2010) Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 69(4): 631-7
22. Swierkot J, Szechinski J (2006) Methotrexate in rheumatoid arthritis. Pharmacol Rep 58(4): 473-92 (Pubitemid 44383273)